Encephalitis related to immunotherapy for lung cancer: Analysis of a multicenter cohort.

 

Lung Cancer.2020 Mar 17;143:36-39.

 

Lien: 10.1016/j.lungcan.2020.03.006

 

Sanchis-Borja M, Ricordel C, Chiappa AM, Hureaux J, Odier L, Jeannin G, Descourt R, Gervais R, Monnet I, Auliac JB, Chouaïd

 

 

First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study.

 

Cancer Med. 2020 Feb 5.

 

Lien : 10.1002/cam4.2806

 

Amrane K, Geier M, Corre R, Léna H, Léveiller G, Gadby F, Lamy R, Bizec JL, Goarant E, Robinet G, Gouva S, Quere G, Abgral R, Schick U, Bernier C, Chouaid C, Descourt R.

 

 

Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018.

 

J Thorac Oncol 2020 Apr;15(4):628-636

 

Lien : 10.1016/j.jtho.2019.12.129

 

Guisier F, Dubos-Arvis C, Viñas F, Doubre H, Ricordel C, Ropert S, Janicot H, Bernardi M, Fournel P, Lamy R, Pérol M, Dauba J, Gonzales G, Falchero L, Decroisette C, Assouline P, Chouaid C, Bylicki O…

 

 

Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma.

 

Medicine (Baltimore). 2020 Jan;99(3):e18726

 

Lien : 10.1097/MD.0000000000018726

 

Bylicki O, Guisier F, Monnet I, Doubre H, Gervais R, Janicot H, Perol M, Fournel P, Lamy R, Auliac JB, Chouaid C.

 

 

Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination for stage-IV non-small-cell lung cancer – VinMetAtezo trial, (GFPC‡ 04-2017). 

 

Future Oncol. 2020 Feb;16(4):5-10

 

Lien :  10.2217/fon-2019-0730

 

Vergnenegre A, Monnet I, Bizieux A, Bernardi M, Chiapa AM, Léna H, Chouaïd C, Robinet G.

 

 

Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small-Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study)

 

Onco Targets Ther. 2020 Dec 30;13:13299-13305

 

Lien : http://10.2147/OTT.S288825

 

Auliac JB, Guisier F, Bizieux A, Assouline P, Bernardini M, Lamy R, Justeau G, François G, Damotte D, Chouaid C

 

 

 

Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019

 

Cancers (Basel). 2020 Dec 2;12(12):3608

 

Lien : http://10.3390/cancers12123608

 

Auliac JB, Bayle S, Do P, Le Garff G, Roa M, Falchero L, Huchot E, Quéré G, Jeannin G, Métivier AC, Hobeika J, Guisier F, Chouaid C

 

 

Second-line therapy for disseminated small-cell lung cancer: optimal management remains to be defined

 

Transl Lung Cancer Res. 2020 Oct;9(5):1732-1735

 

Lien : http://10.21037/tlcr-20-362

 

Chouaid C, Baize N, Monnet I 

 

 

Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14-skipping mutation: A series of 6 cases

 

Lung Cancer. 2020 Dec;150:21-25

 

Lien : http://10.1016/j.lungcan.2020.09.008

 

Mayenga M, Assié JB, Monnet I, Massiani MA, Tabeze L, Friard S, Fraboulet S, Métivier AC, Chouaïd C, Zemoura L, Longchampt E, Callens C, Melaabi S, Couderc LJ, Doubre H

 

 

Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial

 

Lancet Oncol. 2020 Sep;21(9):1224-1233

 

Lien : http://10.1016/S1470-2045(20)30461-7

 

Baize N, Monnet I, Greillier L, Geier M, Lena H, Janicot H, Vergnenegre A, Crequit J, Lamy R, Auliac JB, Letreut J, Le Caer H, Gervais R, Dansin E, Madroszyk A, Renault PA, Le Garff G, Falchero L, Berard H, Schott R, Saulnier P, Chouaid C; Groupe Français de Pneumo-Cancérologie 01–13 investigators

 

 

Targeting the MET-Signaling Pathway in Non-Small-Cell Lung Cancer: Evidence to Date

 

Onco Targets Ther. 2020 Jun 17;13:5691-5706

 

Lien : 10.2147/OTT.S219959

 

Bylicki O, Paleiron N, Assié JB, Chouaid C

 

 

PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 « EPNEC » study

 

Ther Adv Med Oncol. 2020 Jul 7;12

 

Lien : http://10.1177/1758835920937972

 

Arpin D, Charpentier MC, Bernardi M, Monnet I, Boni A, Watkin E, Goubin-Versini I, Lamy R, Gérinière L, Geier M, Forest F, Gervais R, Madrosyk A, Guisier F, Serrand C, Locher C, Decroisette C, Fournel P, Auliac JB, Jeanfaivre T, Letreut J, Doubre H, Francois G, Piton N, Chouaid C, Damotte D